Novel drug development for amyotrophic lateral sclerosis

Journal of the Neurological Sciences

Volumn 180, Issue 1-2, 2000, Pages 21-28

  Hurko, Orest ^a   Walsh, Frank S ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Drug development

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ANTIOXIDANT; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE; CILIARY NEUROTROPHIC FACTOR; DEXTROMETHORPHAN; GABAPENTIN; GROWTH FACTOR; INTERLEUKIN 1; LEUKEMIA INHIBITORY FACTOR; PROTEIN KINASE; RECOMBINANT SOMATOMEDIN C; RILUZOLE; SUPEROXIDE DISMUTASE; TALAMPANEL; TR 500; UNCLASSIFIED DRUG; XALIPRODEN;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DRUG DESIGN; HUMANS;

EID: 0034327342     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(00)00419-6     Document Type: Review

References (106)

1. Pathogenesis of amyotrophic lateral sclerosis: A critical review
2. Treatment of amyotrophic lateral sclerosis
3. A controlled trial of riluzole in amyotrophic lateral sclerosis
4. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
5. The role of excitoxicity in neurodegenerative disease: Implications for therapy
6. Amyotrophic lateral sclerosis: Lessons in trial design from recent trials
7. Avoiding false positive diagnoses of motor neuron disease: Lessons from the Scottish motor neuron disease register
8. The Riluzole early access programme: Descriptive analysis of 844 patients in France
9. Mutations in CuZn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
10. Parkinson's disease research moves on briskly
11. Double-blind, placebo-controlled study to assess safety and efficacy of riluzole as a neuroprotective drug in patients with early, untreated Parkinson's disease
12. Riluzole therapy in patients with Huntington's disease
13. Riluzole, a novel neuroprotective agent, attenuates both neurologic motor and cognitive dysfunction following experimental brain injury in the rat
14. The effect of riluzole on post-traumatic spinal cord injury in the rat
15. Effect of recombinant human insulin-like growth factor-I on progression of ALS: A placebo-controlled study
16. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis
17. Biochemical and electrophysiological properties of SR 57746A, a new, potent 5-HT1A receptor agonist
18. Neurotrophic effects of SR 57746A, a new non-peptide compound: In vitro studies
19. Safety and efficacy controlled trial of SR 57746A in amyotrophic lateral sclerosis
20. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein
21. Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress
22. Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease: A chronic oxidative paradigm for testing antioxidant therapies in vivo
23. The human genome project and the future of medicine
24. 2+] using the fluorometric imaging plate reader (FLIPR)
25. The design of leadlike combinatorial libraries
26. The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing
27. Motor neuron growth factors
28. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III)
29. Placebo-controlled trial of gabapentin in amyotrophic lateral sclerosis
30. The natural history and the effects of gabapentin in amyotrophic lateral sclerosis
31. The effects of ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motorneuropathy
32. The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease
33. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
34. Neuroprotective efficacy of the noncompetitive AMPA receptor antagonist LY300164
35. Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: A preliminary safety and pharmacokinetic study
36. Development of a novel glutathione repleting agent, L-2-oxothiazolidine-4-carboxylic acid (procysteine Rm)
37. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: Evidence for a dual mechanism of action
38. Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes
39. Therapeutic advances in amyotrophic lateral sclerosis
40. Amyotrophic lateral sclerosis, excitotoxicity, and riluzole
41. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis
42. Glutamate, excitotoxicity, and amyotrophic lateral sclerosis
43. Antiglutamate therapy of ALS - Which is the next step?
44. A clinical trial of dextromethorphan in amyotrophic lateral sclerosis
45. A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis
46. Antiglutamate therapy in myotrophic lateral sclerosis: A trial using lamotrigine
47. Multinational trial of branched chain amino acids in amyotrophic lateral sclerosis
48. Familial amyotrophic lateral sclerosis/motor neuron disease (FALS): A review of current developments
49. Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: Evidence for a linked protective factor
50. Amyotrophic lateral sclerosis with mutations in superoxide dismutase: A putative mechanism of degeneration
51. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis
52. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in K(m) for hydrogen peroxide
53. Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis
54. From Charcot to SOD1: Mechanisms of selective motor neuron death in ALS
55. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
56. Creatine monohydrate increases strength in patients with neuromuscular disease
57. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis
58. Identification and characterization of a spinal muscular atrophy-determining gene
59. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
60. Refined mapping and characterization of the recessive familial amyotrophic lateral sclerosis locus (ALS2) on chromosome 2q33
61. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers
62. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34
63. Motor neuron degeneration in mice that express a human Cu Zn superoxide dismutase mutation
64. Experimental models of amyotrophic lateral sclerosis
65. Experimental models for ALS - A short review
66. The Alzheimer's Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice
67. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
68. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits
69. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
70. Transgenic mice expressing Alzheimer amyloid precursor proteins
71. Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript
72. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
73. Formation of polyglutamine inclusions in non-CNS tissue
74. Proximal axonal enlargement in motor neuron disease
75. Lewy-body-like hyaline inclusions in sporadic motor neuron disease are ubiquinated
76. A filamentous inclusion body within anterior horn neurones in motor neurone disease defined by immunohistochemical localization of ubiquitin
77. Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis
78. The Onuf's nucleus and the external and sphincter muscles in amyotrophic lateral sclerosis and Shy-Drager syndrome
79. Nystagmus in motor neuron disease: Clinico pathological study of two cases
80. NMR imaging in ALS
81. Effect of ciliary neurotrophic factor (CNTF) on motoneuron survival
82. Neuronal death in amyotrophic lateral sclerosis is apoptosis: Possible contribution of a programmed cell death mechanism
83. Apoptosis related antigen. Le(y), and nick-end labelling are positive in spinal motor neurons in amyotrophic lateral sclerosis
84. Lack of apoptosis in animals with ALS
85. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase
86. Oxidant treatment causes a dose-dependent phenotype of apoptosis in cultured motoneurons
87. Cobalt prevents nitric-oxide-induced apoptotic motoneuron death in vitro
88. Inhibition of ICE slows ALS in mice
89. Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis
90. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis
91. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group
92. Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy
93. Encapsulated genetically engineered fibroblasts: Release of nerve growth factor and effects in vivo on recovery of cholinergic markers after devascularizing cortical lesions
94. Implanted NGF-producing fibroblasts induce catalase and modify ATP levels but do not affect glutamate receptor binding or NMDA receptor expression in the rat striatum
95. Blood-brain barrier penetration and in vivo activity of an NGF conjugate
96. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors
97. TrkA activation is sufficient to rescue axotomized cholinergic neurons
98. Neurotrophic molecules: Strategies for designing effective therapeutic molecules in neurodegeneration
99. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor
100. AIT-082, a novel purine derivative with neuroregenerative properties
101. Regulation of neuronal survival by the serine-threonine protein kinase Akt
102. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase
103. CEP-1347/KT7515, a JNK pathway inhibitor, supports the in vitro survival of chick embryonic neurons
104. Inhibitors of p38 mitogen-activated protein kinase promote neuronal survival in vitro
105. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway